139,557 Shares in Revvity Inc. $RVTY Bought by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC invested approximately $14.77 million to acquire 139,557 shares of Revvity Inc. in the 1st quarter, making it the firm's 21st largest holding.
• Revvity's stock currently has a market capitalization of $10.04 billion, and despite recent downgrades, it maintains an average rating of "Moderate Buy" from analysts.
• The company recently announced a quarterly dividend of $0.07, with a payout ratio of 11.86%, highlighting its commitment to returning value to shareholders.

Parkman Healthcare Partners LLC purchased a new position in shares of Revvity Inc. (NYSE:RVTY - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 139,557 shares of the company's stock, valued at approximately $14,765,000. Revvity comprises 1.7% of Parkman Healthcare Partners LLC's investment portfolio, making the stock its 21st largest holding. Parkman Healthcare Partners LLC owned 0.12% of Revvity at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of RVTY. AXA S.A. increased its position in Revvity by 72.0% during the fourth quarter. AXA S.A. now owns 4,642 shares of the company's stock worth $518,000 after purchasing an additional 1,943 shares during the last quarter. Ameriprise Financial Inc. increased its position in Revvity by 40.4% during the fourth quarter. Ameriprise Financial Inc. now owns 74,252 shares of the company's stock worth $8,287,000 after purchasing an additional 21,380 shares during the last quarter. BNP Paribas Financial Markets grew its stake in Revvity by 51.6% during the fourth quarter. BNP Paribas Financial Markets now owns 212,367 shares of the company's stock worth $23,702,000 after buying an additional 72,255 shares during the period. Cetera Investment Advisers grew its stake in Revvity by 17.2% during the fourth quarter. Cetera Investment Advisers now owns 5,786 shares of the company's stock worth $646,000 after buying an additional 848 shares during the period. Finally, Deutsche Bank AG grew its stake in Revvity by 43.9% during the fourth quarter. Deutsche Bank AG now owns 550,614 shares of the company's stock worth $61,454,000 after buying an additional 167,918 shares during the period. Institutional investors and hedge funds own 86.65% of the company's stock.

Revvity Stock Down 1.4%

RVTY stock traded down $1.22 during midday trading on Tuesday, hitting $85.06. 907,530 shares of the company's stock were exchanged, compared to its average volume of 1,160,032. The company has a current ratio of 3.33, a quick ratio of 2.75 and a debt-to-equity ratio of 0.43. Revvity Inc. has a 12-month low of $81.36 and a 12-month high of $129.50. The firm has a 50 day moving average price of $92.57 and a 200-day moving average price of $96.72. The stock has a market capitalization of $9.87 billion, a price-to-earnings ratio of 36.04, a price-to-earnings-growth ratio of 2.32 and a beta of 0.94.

Revvity (NYSE:RVTY - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.04. The company had revenue of $720.28 million for the quarter, compared to the consensus estimate of $711.26 million. Revvity had a return on equity of 7.66% and a net margin of 10.19%.Revvity's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.22 EPS. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. On average, analysts anticipate that Revvity Inc. will post 4.94 EPS for the current year.

Revvity Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, November 7th. Investors of record on Friday, October 17th will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Friday, October 17th. Revvity's payout ratio is 11.86%.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on RVTY shares. Evercore ISI decreased their price objective on shares of Revvity from $116.00 to $115.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Raymond James Financial reiterated an "outperform" rating and set a $115.00 price objective (down from $120.00) on shares of Revvity in a research note on Tuesday, July 29th. Stifel Nicolaus decreased their price objective on shares of Revvity from $120.00 to $110.00 and set a "hold" rating for the company in a research note on Tuesday, July 29th. Bank of America decreased their price objective on shares of Revvity from $116.00 to $110.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Finally, Wall Street Zen downgraded shares of Revvity from a "buy" rating to a "hold" rating in a research note on Sunday, August 3rd. Ten equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $120.07.

Revvity Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.